Business Wire

Ant Group’s INCLUSION Fintech Conference Debuts in Shanghai

24.9.2020 12:00:00 EEST | Business Wire | Press release

Share

Ant Group, an innovative technology provider, today officially launched its inaugural INCLUSION Fintech Conference, welcoming prominent speakers from all corners of the world, including representatives from the United Nations and the International Monetary Fund, as well as Nobel Prize-winning scholars, to participate in a wide-ranging conversation on how digital technology can help build a more inclusive, green, and sustainable world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005369/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IMF Managing Director Kristalina Georgieva delivers keynote speech at inaugural INCLUSION Fintech Conference (Photo: Business Wire)

Taking place both online and onsite in Shanghai from September 24-26, 2020, the conference brings together thought leaders from across the globe to envision the digital economy of the future. The first day of the conference began with a morning plenary session, followed by 17 forums in the afternoon and a nature-themed music festival along Shanghai’s iconic Huangpu River in the evening.

An offline 13,000sqm exhibition area showcased the latest fintech innovations and technology solutions from Ant Group and Alipay, as well as a variety of other major companies from the technology and financial communities, including Kenyan telecommunications provider Safaricom, Swiss-Thai fintech company Ascend Money, and US financial services company Mastercard.

Key highlights from the first day of the INCLUSION Fintech Conference include:

  • Kristalina Georgieva, Managing Director of the International Monetary Fund (IMF), provided a comprehensive overview of the global economic outlook, highlighting the pivotal role financial inclusion can play in building a better and more resilient world, especially as economies and businesses continue to recover from the COVID-19 pandemic.

IMF Managing Director Kristalina Georgieva delivers keynote speech at inaugural INCLUSION Fintech Conference

“Fintech is already playing an important part in slowing the spread of COVID-19,” emphasized Ms. Georgieva. “It has made contactless and cashless transactions very popular and very useful. Digital financial services also enable governments to quickly expand social safety nets and help facilitate direct payments between people, in turn accelerating economic recovery.”

  • During the plenary session, Eric Jing, Executive Chairman of Ant Group, envisioned a new financial ecosystem that is powered by technological innovation. He stressed that digital technology accelerates the evolution of financial services and makes it more accessible to those in need, bringing equal development opportunities for all.
  • Simon Hu, CEO of Ant Group, emphasized that technology is at the heart of Ant Group’s DNA. “Since our inception over 16 years ago, digital technology has been part and parcel of everything we do, continuously driving the evolution of our strategy, operations, and value proposition.”
  • United Nations Development Progamme Administrator Achim Steiner said: "COVID is accelerating digitization and the dividend could be huge, from helping to deliver our climate goals to improving health and education access. Whether we can actually benefit from the digital transformation, however, depends on how digitalization reshapes finance. The time has come for the financial system to fulfill people’s needs, the ultimate owners of the world’s financial assets – digitalization can fuel that change."
  • Nobel Economics Laureates Michael Spence and Bengt Holmström also shared their views and insights on the current state of global finance and the integration of technology and financial services in a conversation with Long Chen, director of the Luohan Academy, an open-research initiative by Alibaba Group.
  • Forums in the afternoon focused on an array of different topics, including open banking, insurance and technology, and new methods of global remittance, amongst many others.

A full playback of the plenary session will be available on the INCLUSION Fintech Conference’s YouTube channel as well as on the conference’s official website.

About the INCLUSION Fintech Conference

The INCLUSION Fintech Conference was officially announced in January 2020 to bring together the global financial and technology communities, to envision a world that is more inclusive, green, and sustainable through digital technology. The inaugural three-day conference in Shanghai, to be held on September 24-26, 2020, will feature over 40 forums, with keynotes and panels covering major themes such as the global digital economy, digital finance, innovative technology, and sustainability.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries
Daryl Loo
Ant Group
looliatliang.dlll@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye